Robust Price Performance and Market Context
Trading at ₹927.50, Venus Remedies is nearing its 52-week high of ₹939.45, having surged from a low of ₹277.85 over the past year. The stock’s daily range on 13 Mar 2026 spanned ₹862.05 to ₹939.45, underscoring strong intraday buying interest. This price action contrasts sharply with the broader market, as the Sensex has declined by 10.78% year-to-date, while Venus Remedies has gained 20.93% in the same period. Over longer horizons, the stock’s returns are even more impressive, with a 1-year return of 217.69% and a 10-year return of 901.62%, vastly outperforming the Sensex’s 2.71% and 207.61% respectively.
Technical Trend Upgrade and Moving Averages
The technical trend for Venus Remedies has shifted from mildly bullish to bullish, supported by daily moving averages that are firmly positive. The stock’s price currently trades above key moving averages, signalling strong upward momentum. This alignment of moving averages typically indicates a favourable environment for buyers, reducing downside risk and enhancing the probability of continued gains.
MACD and Momentum Oscillators
The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly basis, the MACD remains mildly bearish, suggesting some short-term consolidation or profit-taking may occur. However, the monthly MACD is bullish, indicating that the longer-term momentum remains firmly positive. This divergence between weekly and monthly MACD readings often precedes a sustained rally once short-term corrections conclude.
RSI and Bollinger Bands Analysis
The Relative Strength Index (RSI) currently shows no definitive signal on both weekly and monthly charts, implying the stock is not yet overbought or oversold. This neutral RSI reading suggests room for further price appreciation without immediate risk of a sharp reversal. Meanwhile, Bollinger Bands are bullish on both weekly and monthly timeframes, reflecting expanding volatility with upward price pressure. The price touching the upper band today reinforces the strength of the current rally.
Additional Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator is mildly bearish on the weekly chart but bullish on the monthly, mirroring the MACD’s mixed signals. Dow Theory analysis supports a weekly bullish trend, though no clear monthly trend is established yet. On balance, the On-Balance Volume (OBV) indicator is mildly bullish weekly but mildly bearish monthly, indicating that volume flows are somewhat mixed but generally supportive of the recent price gains.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Mojo Score and Grade Upgrade
MarketsMOJO has upgraded Venus Remedies’ Mojo Grade from Hold to Buy as of 12 Mar 2026, reflecting improved technical and fundamental outlooks. The company’s Mojo Score stands at a robust 74.0, signalling strong overall quality and momentum. This upgrade is significant for investors seeking stocks with favourable risk-reward profiles, especially in the pharmaceuticals and biotechnology sector where Venus Remedies operates.
Comparative Industry and Sector Positioning
Within the Pharmaceuticals & Biotechnology sector, Venus Remedies’ technical indicators and price momentum stand out. The micro-cap classification highlights the stock’s growth potential, albeit with higher volatility. Its recent outperformance relative to the Sensex and sector peers suggests that the company is benefiting from both sector tailwinds and company-specific catalysts.
Long-Term Return Analysis
Venus Remedies’ extraordinary long-term returns underscore its strong growth trajectory. Over five years, the stock has delivered a 292.18% return compared to the Sensex’s 49.70%. Over three years, the stock’s 452.25% gain dwarfs the Sensex’s 28.58%. These figures highlight the company’s ability to generate substantial shareholder value, supported by favourable technical trends and improving fundamentals.
Risks and Considerations
Despite the bullish technical signals, investors should remain mindful of the mildly bearish weekly MACD and KST indicators, which may signal short-term volatility or consolidation phases. Additionally, the micro-cap status entails liquidity and volatility risks. However, the neutral RSI and bullish Bollinger Bands suggest that the current rally has room to run before becoming overextended.
Want to dive deeper on Venus Remedies Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Outlook and Investor Implications
Given the convergence of bullish technical signals on daily and monthly charts, alongside a significant Mojo Grade upgrade, Venus Remedies Ltd appears poised for further gains. The stock’s strong relative performance versus the Sensex and its sector peers reinforces its appeal as a growth-oriented investment. Investors with a tolerance for micro-cap volatility may find this an opportune moment to consider exposure, especially as the stock approaches its 52-week high.
Monitoring the weekly MACD and KST indicators will be crucial to gauge short-term momentum shifts, while the neutral RSI suggests that the stock is not yet overbought. The bullish Bollinger Bands and moving averages provide additional confirmation of a sustained upward trend. Overall, Venus Remedies is demonstrating a compelling technical setup that aligns with its fundamental strengths.
Summary
Venus Remedies Ltd’s recent price momentum and technical upgrades mark a pivotal moment for the stock. The combination of a 7.46% daily gain, a Mojo Grade upgrade to Buy, and strong long-term returns relative to the Sensex highlight its potential as a high-growth micro-cap pharmaceutical stock. While short-term caution is warranted due to some mildly bearish weekly indicators, the broader technical landscape supports a bullish outlook. Investors should consider this stock within a diversified portfolio, keeping an eye on evolving momentum signals and sector dynamics.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
